* * REVISED TIME * * CytoDyn to Hold Webcast on October 20 to Discuss DSMC’s Recommendations from the Interim Analysis of the Phase 2b/3 Clinical Trial for Severe-to-Critical COVID-19 Patients

Rhea-AI Summary

CytoDyn Inc. (OTC.QB: CYDY) announced an investment community webcast on October 20, 2020, at 2:00 pm PT to discuss the Data Safety Monitoring Committee's recommendations following an interim analysis of 195 patients in its Phase 2b/3 clinical trial for severe-to-critical COVID-19. The webcast will feature a presentation and a Q&A session. The event is accessible via the company's website and will be archived for 30 days after the event.

Positive

• The Data Safety Monitoring Committee's recommendations may provide a potential regulatory path forward for leronlimab.

Negative

• No specific clinical trial results were disclosed, leaving uncertainty regarding the trial's effectiveness.
• The focus on severe-to-critical COVID-19 suggests the potential for limited patient response or market limitation.

VANCOUVER, Washington, Oct. 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community webcast on Tuesday, October 20, 2020, at a new time 2:00 pm PT / 5:00 pm ET, which is one hour later than the previously announced time.

Management will discuss the recommendations of the Data Safety Monitoring Committee (DSMC) following their review of the interim analysis of the first 195 patients enrolled in the Company’s Phase 2b/3 clinical trial for patients with severe-to-critical COVID-19 indications, including a potential regulatory path forward.

Management will also present slides during the webcast followed by approximately 30-45 minutes to address questions submitted online by analysts and investors.

Date: Tuesday, October 20, 2020
Time: 2:00 pm PT / 5:00 pm ET (NEW REVISED TIME)
Dial-In: None.
Questions: Can be submitted online through the link noted below.

This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. The webcast can also be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/41443/indexl.html

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until November 20, 2020.

CONTACTS
Investors:
Michael Mulholland
Office: 360.980.8524, ext. 102
mmulholland@cytodyn.com

FAQ

What is the purpose of CytoDyn's Phase 2b/3 clinical trial for leronlimab?

The trial aims to evaluate the effectiveness of leronlimab in treating severe-to-critical COVID-19 patients.

What is being discussed in CytoDyn's upcoming webcast?

The webcast will cover recommendations from the Data Safety Monitoring Committee regarding the interim analysis of the clinical trial.

When is the CytoDyn investment community webcast scheduled?

The webcast is scheduled for October 20, 2020, at 2:00 pm PT.

How can I access the CytoDyn webcast?

The webcast can be accessed on CytoDyn's corporate website under the Investors section.